BioSpace News Archive

Year

• 2005
• 2006
• 2007
• 2008
• 2009
• 2010
• 2011
• 2012
• 2013
• 2014
• 2015
• 2016
• 2017
• 2018
• 2019
• 2020
• 2021
• 2022
• 2023
• 2024
• 2025

Month

• January
• February
• March
• April
• May
• June
• July
• August
• September
• October
• November
• December

Day

• 1
• 2
• 3
• 4
• 5
• 6
• 7
• 8
• 9
• 10
• 11
• 12
• 13
• 14
• 15
• 16
• 17
• 18
• 19
• 20
• 21
• 22
• 23
• 24
• 25
• 26
• 27
• 28
• 29
• 30

• 

  Drug Development

  Ipsen Inks Potential $900M Deal with Sutro for Global Rights to Preclinical ADC

  Under the agreement, Ipsen nabs exclusive global rights for development and commercialization of Sutro Biopharma’s STRO-003, an antibody-drug conjugate which is completing the final stages of preclinical development.

  April 2, 2024

   · 

  2 min read

   · 

  Tyler Patchen
• 

  Drug Development

  The Next Wave of ADCs Could Treat Evasive Solid Tumors

  With second-generation antibody-drug conjugates, Eli Lilly, Daiichi Sankyo and others look to reduce toxicity and improve the magnitude and duration of response.

  April 2, 2024

   · 

  6 min read

   · 

  Heather McKenzie
• 

  Drug Development

  Vertex Pushes Oral Drug into Phase III Kidney Disease Trial, Eyes Accelerated Approval

  Following promising Phase IIa data, Vertex Pharmaceuticals will now evaluate its oral drug candidate inaxaplin in a late-stage study of APOL-1 mediated kidney disease.

  April 2, 2024

   · 

  2 min read

   · 

  Tristan Manalac
• 

  Drug Development

  Verve Halts Trial for Lead Gene Editing Program Due to Safety Concerns

  Verve Therapeutics is pausing enrollment in the Phase Ib Heart-1 study for its gene editor VERVE-101 after a patient developed grade 3 laboratory abnormalities, the company announced Tuesday.

  April 2, 2024

   · 

  2 min read

   · 

  Tristan Manalac
• 

  Business

  Moderna Moves Cambridge Employees Into New Headquarters

  The new Cambridge, Mass.–based facility is about 460,000 square feet. Labs occupy nearly 50% of the space.

  April 2, 2024

   · 

  4 min read

   · 

  Angela Gabriel
• 

  Deals

  Eiger Files for Bankruptcy, Plans to Shutter Operations After Difficult Year

  Following a series of rejections and clinical failures, Eiger BioPharmaceuticals has declared bankruptcy and will sell all its assets as the company winds down operations.

  April 2, 2024

   · 

  2 min read

   · 

  Tristan Manalac
• 

  Drug Development

  Roivant Posts Phase II Eye Disease Win for TYK2 Drug, Plans Pivotal Program

  Roivant has chalked up a mid-stage victory for its Pfizer-partnered dual TYK2/JAK1 inhibitor, setting it up to start a Phase III trial in non-anterior non-infectious uveitis this year.

  April 2, 2024

   · 

  2 min read

   · 

  Nick Paul Taylor
• 

  Business

  C-Suite Shuffle: Lonza Hires New CEO

  Read the latest overview of people coming and going from executive positions at biopharma companies that BioSpace covers.

  April 2, 2024

   · 

  2 min read

   · 

  Neil Versel
• 

  FDA

  Did WuXi Make a Whoopsie? US-China R&D Relations in Limbo

  Plus, another big buy points to strength of CDMO market and a new treatment for pulmonary arterial hypertension

  April 2, 2024

   · 

  1 min read

   · 

  Greg Slabodkin, Heather McKenzie, Tyler Patchen
• 

  Policy

  Teva, Viatris Again Challenge J&J Patent for Schizophrenia Drug with Appeals Court Win

  A federal appeals court Monday backed Teva and Viatris’ challenge to a lower court ruling, finding that the companies can again make their case against Johnson & Johnson’s patent covering its schizophrenia drug Invega Sustenna.

  April 2, 2024

   · 

  2 min read

   · 

  Tristan Manalac